Hypochlorous Acid-Activated UCNPs-LMB/VQIVYK Multifunctional Nanosystem for Alzheimer’s Disease Treatment
Source abstract
Abstract
The development of nanosystems, which can photooxygenate amyloid-β (Aβ), detect the Tau protein, and inhibit effectively the Tau aggregation, is increasingly important in the diagnosis and therapy of Alzheimer’s disease (AD). Herein, UCNPs-LMB/VQIVYK (UCNPs: upconversion nanoparticles, LMB: Leucomethylene blue, and VQIVYK: Biocompatible peptide) is designed as a HOCl-controlled released nanosystem for AD synergistic treatment. Under exposure to high levels of HOCl, the released MB from UCNPs-LMB/VQIVYK will produce singlet oxygen (1O2) under red light to depolymerize Aβ aggregation and reduce cytotoxicity. Meanwhile, UCNPs-LMB/VQIVYK can act as an inhibitor to decrease Tau-induced neurotoxicity. Besides, UCNPs-LMB/VQIVYK can be used for upconversion luminescence (UCL) due to its unexceptionable luminescence properties. This HOCl-responsive nanosystem offers a new therapy for AD treatment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Carbon and Quantum Dots Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Molecular Sciences and Engineering, Institute of Frontier and Interdisciplinarity Science, Shandong University, Qingdao 266237, China
Center for Biotechnology and Biomedical Engineering, Yiwu Research Institute of Fudan University, Yiwu 322000, China
College of Pharmacy, Jiamusi University, Jiamusi 154007, China
Funding
National Natural Science Foundation of China
References (56)
Show source-provided references
1. Pathways towards and away from Alzheimer’s disease10.1038/nature02621 ↗
2. Alzheimer’s disease10.1016/S0140-6736(06)69113-7 ↗
3. An in situ-triggered and chemi-excited photooxygenation system for Aβ aggregates10.1016/j.cej.2022.140998 ↗
4. Amyloid-beta plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation10.1038/nm.4443 ↗
5. Structural absorption by barbule microstructures of super black bird of paradise feathers10.1038/s41467-017-02088-w ↗
6. Selective amyloid beta oligomer assay based on abasic site-containing molecular beacon and enzyme-free amplification10.1016/j.bios.2015.11.048 ↗
7. The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics10.1126/science.1072994 ↗
8. The amyloid beta peptide: A chemist’s perspective. Role in Alzheimer’s and fibrillization10.1021/cr3000994 ↗
9. The Natively Unfolded Character of Tau and Its Aggregation to Alzheimer-like Paired Helical Filaments10.1021/bi800783d ↗
10. Genetic ablation of tau improves mitochondrial function and cognitive abilities in the hippocampus10.1016/j.redox.2018.07.010 ↗
11. Near-Infrared Switchable Fullerene-Based Synergy Therapy for Alzheimer’s Disease10.1002/smll.201801852 ↗
12. High-sensitivity imaging of time-domain near-infrared light transducer10.1038/s41566-019-0437-z ↗
13. Fine-Tuning Ho-Based Red-Upconversion Luminescence by Altering NaHoF4 Core Size and NaYbF4 Shell Thickness10.1021/acs.chemmater.9b01944 ↗
14. Black Phosphorus Nanosheet-Based Drug Delivery System for Synergistic Photodynamic/Photothermal/Chemotherapy of Cancer10.1002/adma.201603864 ↗
15. Nanocaged platforms: Modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger10.1039/C6NR07315H ↗
16. Design of Luminescent Inorganic Materials: New Photophysical Processes Studied by Optical Spectroscopy10.1021/ar990102y ↗
17. Upconversion nanoparticles: Design, nanochemistry, and applications in theranostics10.1021/cr400425h ↗
18. Lanthanide luminescence for functional materials and bio-sciences10.1039/B905604C ↗
19. Recent progress in rare earth micro/nanocrystals: Soft chemical synthesis, luminescent properties, and biomedical applications10.1021/cr4001594 ↗
20. Engineering bright sub-10-nm upconverting nanocrystals for single-molecule imaging10.1038/nnano.2014.29 ↗
21. Upconverting nanoparticles10.1002/anie.201005159 ↗
22. Lanthanide-doped LiLuF(4) upconversion nanoprobes for the detection of disease biomarkers10.1002/anie.201309503 ↗
23. Are rare-earth nanoparticles suitable for in vivo applications?10.1002/adma.201305535 ↗
24. Multicolor barcoding in a single upconversion crystal10.1021/ja5013646 ↗
25. Upconversion nanophosphors for small-animal imaging10.1039/C1CS15187H ↗
26. Nanoparticle-based systems for T(1)-weighted magnetic resonance imaging contrast agents10.3390/ijms140510591 ↗
27. Dual-Targeting Upconversion Nanoprobes across the Blood–Brain Barrier for Magnetic Resonance/Fluorescence Imaging of Intracranial Glioblastoma10.1021/nn406197c ↗
28. Photodynamic therapy (PDT) for lung cancer10.1016/j.pdpdt.2011.03.342 ↗
29. Self-assembled CeVO4/Ag nanohybrid as photoconversion agents with enhanced solar-driven photocatalysis and NIR-responsive photothermal/photodynamic synergistic therapy performance10.1039/C9NR02412C ↗
30. Beating cancer in multiple ways using nanogold10.1039/c0cs00180e ↗
31. Near-Infrared Organic Dye-Based Nanoagent for the Photothermal Therapy of Cancer10.1021/acsami.6b07838 ↗
32. Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness10.1038/s41598-016-0028-x ↗
33. Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications10.1016/S1572-1000(05)00097-9 ↗
34. Rational design of phenothiazinium derivatives and photoantimicrobial drug discovery10.1016/j.dyepig.2016.09.015 ↗
35. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines10.1073/pnas.93.20.11213 ↗
36. Inhibition of tau-derived hexapeptide aggregation and toxicity by a self-assembled cyclic d,l-alpha-peptide conformational inhibitor10.1039/C8CC01233D ↗
37. The formation of straight and twisted filaments from short tau peptides10.1074/jbc.M402379200 ↗
38. Unambiguous Detection of Elevated Levels of Hypochlorous Acid in Double Transgenic AD Mouse Brain10.1021/acschemneuro.9b00554 ↗
39. Tumor-Microenvironment-Activated Reactive Oxygen Species Amplifier for Enzymatic Cascade Cancer Starvation/Chemodynamic /Immunotherapy10.1002/adma.202106010 ↗
40. UV-Emitting Upconversion-Based TiO2 Photosensitizing Nanoplatform: Near-Infrared Light Mediated in Vivo Photodynamic Therapy via Mitochondria-Involved Apoptosis Pathway10.1021/nn506107c ↗
41. Phenanthriplatin(iv) conjugated multifunctional up-converting nanoparticles for drug delivery and biomedical imaging10.1039/C8TB01034J ↗
42. New insights in amyloid beta interactions with human telomerase10.1021/ja511030s ↗
43. Polymer-Coated NaYF4:Yb3+, Er3+ Upconversion Nanoparticles for Charge-Dependent Cellular Imaging10.1021/nn201896m ↗
44. Rational Surface Design of Upconversion Nanoparticles with Polyethylenimine Coating for Biomedical Applications: Better Safe than Brighter?10.1021/acsbiomaterials.8b00633 ↗
45. Nanotechnologies for Alzheimer’s disease: Diagnosis, therapy, and safety issues10.1016/j.nano.2011.03.008 ↗
46. Metallosupramolecular complex targeting an α/β discordant stretch of amyloid β peptide10.1039/c2sc20372c ↗
47. Assembly of τ protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming β structure10.1073/pnas.97.10.5129 ↗
48. Charge-Pairing Mechanism of Phosphorylation Effect upon Amyloid Fibrillation of Human Tau Core Peptide10.1021/bi8010994 ↗
49. Inhibition of the Aggregation and Toxicity of the Minimal Amyloidogenic Fragment of Tau by Its Pro-Substituted Analogues10.1002/chem.201701218 ↗
50. Selective Inhibition of Aggregation and Toxicity of a Tau-Derived Peptide using Its Glycosylated Analogues10.1002/chem.201504950 ↗
51. Mechanistic insights into remodeled Tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids10.1038/s41598-017-18443-2 ↗
52. Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold10.1016/j.ejmech.2016.01.006 ↗
53. D-ribose and pathogenesis of Alzheimer’s disease10.1007/s11033-020-05243-7 ↗
54. The Pathogenesis of Alzheimer’s Disease and the Role of Aβ4210.1017/S1092852900025876 ↗
55. Nanomaterials for the treatment and diagnosis of Alzheimer’s disease: An overview10.1016/j.impact.2020.100251 ↗
56. H2O2-responsive multifunctional nanocomposite for the inhibition of amyloid-β and Tau aggregation in Alzheimer’s disease10.1002/bmm2.12011 ↗